Alaska Medicaid and GLP-1s

What changed, and what the document says

1. One class code, three drugs, no criteria

   Conditions apply

   The entire published requirement for these products is this line. It asks for a labeled indication and says nothing about weight, BMI or a sleep study.

   “Class 0: verification of covered, labeled indication required”

   Alaska Department of Health — Last Updated 07/28/2026

2. The list is interim, and says so in its title

   Context

   Alaska calls its own document interim, which is a fair description of a policy expressed as a spreadsheet row.

   “Alaska Medicaid Interim Prior Authorization List”

   Alaska Department of Health — Last Updated 07/28/2026

3. Mounjaro is treated more harshly than Zepbound

   Context

   The diabetes product carries a step-therapy class while the obesity-labeled one does not — the opposite of the pattern in most states here.

   “Class 2: at least 2 previously failed therapies required”

   Alaska Department of Health — Last Updated 07/28/2026

4. Read on a list updated in July

   Context

   The date matters because a row can be added or removed without any bulletin anywhere.

   “Last Updated 07/28/2026”

   Alaska Department of Health — Last Updated 07/28/2026

5. The drug list does not mention them at all

   Context

   All 5,825 non-blank lines of the June 2026 drug list were read. None of the three weight-management products appears, and neither does the word obesity or the word weight — while every diabetes GLP-1 is there, which is what shows the scan works.

   “Effective Date 06/01/2026”

   Alaska Department of Health — Effective Date 06/01/2026

What the state didn't publish

Alaska's Medicaid drug list names no weight-management GLP-1, and does not contain the word obesity or the word weight anywhere.

We checked all 5,825 non-blank lines of the Preferred Drug List effective June 1, 2026, read as text end to end.

Within the same 5,825 lines of the drug list, insulin appears 197 times, metformin 129 times, Mounjaro and Trulicity 6 times each, Ozempic 5 times, Rybelsus 4 times and Victoza once. Those lines contain no occurrences of Wegovy, Zepbound, Saxenda, obesity or weight.

Source: Alaska Medicaid Preferred Drug List (PDL), Alaska Department of Health.

Which of these companies serve Alaska?

Of the 387 companies we grade, 34 publish a list of the states they are licensed in. We checked 251 more and found no such list on any page we read; 102 we have not checked either way.

16 of those lists name Alaska: Gala Health, Care Bare Rx, Vita Bella, Levity, Wisp, WePeptideRx, Ways2Well, TeleClinic, Tyde Wellness, Trimi, Enhance MD, HumeCare+, Mojoon, Peak Wellness, Sprout Health, and Allara Health. That is a licensure claim each company makes about itself, not something we checked with a state board.

A published list is a starting point, not a guarantee. If availability decides your choice, ask before you pay and get the answer in writing.

Coverage decides what you pay before cash does. See how state Medicaid programs cover GLP-1s and what a prior-authorization denial turns on.